Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CORRECTION OFFICIAL - West Pharmaceutical Services Inc Lowers FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance


Thursday, 1 Aug 2013 09:34am EDT 

CORRECTED TO READ - "earnings per share (EPS) in the range of $3.13-$3.28 "... INSTEAD OF ... "earnings per share (EPS) in the range of $3.13-$3.23"... IN THE BODY. West Pharmaceutical Services Inc updated fiscal 2013 guidance and expects consolidated net sales in the range of $1.350-$1.390 billion compared to prior range of $1.360 to $1.400 billion, full-Year diluted earnings per share (EPS) in the range of $3.13-$3.28 compared to prior range of $3.08-$3.23 and Full-Year adjusted diluted EPS of $3.10-$3.25 compared to prior range of $3.05-$3.20. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.37 billion and EPS of $3.14 for fiscal 2013. 

Company Quote

45.48
0.38 +0.84%
24 Oct 2014